Halozyme Therapeutics Updates

Halozyme Therapeutics, Inc. (NASDAQ:HALO). Last Market Price: 7.35, Change: +1.15, % Change: (18.55%). Shares trade in the range of 6.96 – 7.55 dollars. It has a market capitalization of 761.60M dollars, making it a Small Cap Stock and has 103.62M outstanding shares. The company has a beta of 1.49, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.37. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 49%. The company has a 52 week high of $ 8.13 and a 52 week low of $ 5.54. Average volumes of shares traded daily are 473,991. Volume traded in the last session was at 1,550,000, 3.27 times the average volume.

• Halozyme Therapeutics provides results from Roche’s subcutaneous herceptin Phase 3 Trial
• Company announces that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous injection of Herceptin, experienced comparable results to Herceptin given as an intravenous infusion.

For Q2 (Jun ’11), It had a Net profit margin of 13.44%, an Operating margin of 13.35%. Other Key stats and ratios are : Return on average assets of 14.67%, Return on average equity of 74.47%. The organization has an employee strength of 102

Consensus Recommendation is a Buy.

Estimate for sales for the Year Ending Dec-11 show a mean of 50.24 million dollars, an estimate high of 60.15 million dollars and an estimate low of 27.00 million dollars. A year ago the figures stood at 23.36 million dollars.

Estimate for sales for the Year Ending Dec-12 show a mean of 33.55 million dollars, an estimate high of 56.56 million dollars and an estimate low of 12.00 million dollars. A year ago the figures stood at 61.32 million dollars.

Estimate for EPS for the Year Ending Dec-11 show a mean of -0.28 dollars, an estimate high of -0.18 dollars and an estimate low of -0.46 dollars. A year ago the figures stood at -0.51 dollars.

Estimate for EPS for the Year Ending Dec-12 show a mean of -0.45 dollars, an estimate high of -0.25 dollars and an estimate low of -0.69 dollars. A year ago the figures stood at -0.15 dollars.

Sales for Quarter Ending Jun-11 was estimated at 5.64 million dollars, however the actual sales figure stood at 23.19 million dollars, 17.55 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 4.74 million dollars, however the actual sales figure stood at 7.54 million dollars, 2.8 million dollars more than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.